Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.43 |
| ▸ | CLK2 | P49760 | 8/20 | 0.43 |
| ▸ | CLK3 | P49761 | 8/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558639 | 0.88 | SRC (0.41) | SRCCHEK1ACHEJAK2 | |
| SCHEMBL2400727 | 0.87 | LRRK2 (0.48) | DYRK1ACLK2CLK3CHEK1WNT1 | |
| SCHEMBL1558939 | 0.84 | ALDH1A1 (0.42) | KCNH2CHEK1JAK2 | |
| SCHEMBL1558859 | 0.84 | DGAT1 (0.45) | KCNH2 | |
| SCHEMBL1558837 | 0.81 | LRRK2 (0.43) | CHEK1 | |
| SCHEMBL1557449 | 0.81 | LRRK2 (0.42) | CHEK1ACHE | |
| SCHEMBL2394460 | 0.81 | LRRK2 (0.52) | — | |
| SCHEMBL12266421 | 0.81 | MTOR (0.42) | CHEK1 | |
| SCHEMBL2398394 | 0.81 | DYRK1A (0.47) | DYRK1ACLK2CLK3CHEK1WNT1 | |
| SCHEMBL2396054 | 0.80 | MAP4K4 (0.46) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | GSK3B 47/4885KCNH2 2054/4885DYRK1A 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.